Semaglutide news covers the latest GLP-1 trial results, oral pill approvals, pricing changes, and side effect warnings—plus what US patients should know now.
Semaglutide news in 2025 focuses on three storylines: oral versions of the drug moving toward pharmacy shelves, combination treatments that pair semaglutide with cagrilintide, and a steady flow of safety, pricing, and legal updates in the United States. Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, and it is not a cure for either condition. Most headlines come from clinical trial readouts, regulatory decisions, and court fights over compounded copies of the drug.
Why Semaglutide Stays in the Headlines
If you follow semaglutide news today, the questions have changed. Fewer stories ask whether GLP-1 drugs work and more ask who can get them, in what form, and at what cost.
Three forces keep the topic in the news cycle:
- Demand. Millions of US adults have used a GLP-1 medication, and supply has repeatedly fallen short of prescriptions.
- Competition. Novo Nordisk, Eli Lilly, and smaller biotechs keep releasing data on next-generation obesity drugs.
- Scrutiny. Regulators, insurers, and plaintiff attorneys are all examining side effects, marketing, and compounding practices.
Oral Semaglutide and New Formulations
Rybelsus, the oral form of semaglutide, has been FDA-approved for type 2 diabetes since 2019. Novo Nordisk has also submitted an oral Wegovy tablet for chronic weight management, and a regulatory decision is expected within the next year.
The active ingredient is the same in the pill and the injection, but absorption is not. Oral semaglutide must be taken on an empty stomach with a small sip of water, and it generally produces less weight loss than the injectable version.
Some compounding pharmacies mixed semaglutide with vitamin B12 or other additives to soften injection-site reactions. Compounded products are not FDA-approved, and the agency has warned that some copies contained impurities or incorrect doses.
| Product | Active ingredient | How it is taken | Approved use |
|---|---|---|---|
| Ozempic | Semaglutide | Weekly injection | Type 2 diabetes |
| Wegovy | Semaglutide | Weekly injection | Chronic weight management |
| Rybelsus | Semaglutide | Daily tablet | Type 2 diabetes |
| Compounded semaglutide | Semaglutide plus undisclosed additives | Injection, drops, or tablets | Not FDA-approved |
CagriSema and the Combination Therapy Race
CagriSema pairs cagrilintide and semaglutide in a single weekly injection. In the REDEFINE-1 trial, adults with obesity lost roughly 22.7% of their body weight over 68 weeks, which is the strongest result reported for the combination so far, even though it fell short of the 25% the company had projected.
Dosing follows a gradual step-up schedule similar to standard GLP-1 titration. Research protocols for cagrilintide semaglutide dosage typically start low and increase every four weeks to limit nausea and other gastrointestinal effects.
| Treatment | Components | Average weight loss in trials | Status |
|---|---|---|---|
| CagriSema | Semaglutide + cagrilintide | About 22.7% at 68 weeks | Phase 3 complete; under regulatory review |
| Wegovy | Semaglutide 2.4 mg | About 15% at 68 weeks | FDA-approved |
| Zepbound | Tirzepatide (GIP/GLP-1) | About 21% at 72 weeks | FDA-approved |
Heart, Kidney, and Other Emerging Uses
The SELECT trial found that semaglutide 2.4 mg cut major cardiovascular events by about 20% in adults with overweight or obesity and existing heart disease. That finding supported a new FDA label indication and shifted how cardiologists talk about the drug.
The FLOW trial showed slower progression of chronic kidney disease in people with type 2 diabetes. Smaller studies have reported reduced knee osteoarthritis pain and possible signals in alcohol use disorder, but those results remain preliminary.
Alzheimer's research is still in progress. Two large trials, EVOKE and EVOKE Plus, are testing whether semaglutide slows early disease progression, with results expected in 2026.
Safety Updates and Side Effects
Gastrointestinal upset is still the most common complaint. Common semaglutide side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, and they often ease as the body adjusts to a dose.
More serious reports include pancreatitis, gallbladder disease, gastroparesis, and a rare optic nerve condition called NAION. The FDA added a warning about aspiration risk during anesthesia, and anesthesiology groups now recommend pausing the drug before elective surgery.
Search interest in semaglutide side effects cancer has grown since rodent studies linked the drug class to thyroid C-cell tumors. Regulators say the human relevance of those animal findings is unknown, and no causal link to cancer in people has been established.
Semaglutide is not recommended for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. People with persistent severe symptoms should contact a healthcare professional rather than change their dose on their own.
Pricing, Access, and Compounding Rules
The FDA declared the semaglutide shortage resolved in early 2025, which ended most large-scale compounding of copies. Some state-licensed pharmacies continue to operate in narrow legal gray areas, and lawsuits over compounded products are still moving through the courts.
Cash prices have dropped. Manufacturers now sell some products directly to patients through telehealth partners, and semaglutide was selected for Medicare drug price negotiation, with negotiated prices scheduled to begin in 2027.
Gray-market sellers sometimes promote research peptides, including aod 9604 and semaglutide, as a fat-loss stack. AOD-9604 is not approved for human use in the United States, and no clinical trial has tested the combination.
What to Watch Next
Watch for an FDA decision on oral Wegovy, final review timelines for CagriSema, and results from the Alzheimer's trials. Insurance coverage rules may change faster than any of the science.
Semaglutide remains a prescription medicine with real benefits and real risks. Any decision to start, stop, or switch treatments should be made with a licensed clinician who knows your medical history.
Frequently Asked Questions
Is there an oral version of Wegovy available now?
Not yet for weight management. Rybelsus, an oral semaglutide tablet, is FDA-approved for type 2 diabetes, and Novo Nordisk has submitted an oral Wegovy 25 mg tablet for chronic weight management. An FDA decision is expected within the next year.
Does semaglutide cause cancer in humans?
No confirmed causal link to cancer in humans has been established. Rodent studies found thyroid C-cell tumors, which is why semaglutide carries a boxed warning and is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2. The FDA states that the human relevance of those animal findings is unknown.
Can I still get compounded semaglutide in the US?
Large-scale compounding largely ended after the FDA declared the semaglutide shortage resolved in early 2025. Some state-licensed pharmacies may still prepare copies under limited legal exceptions, but compounded semaglutide is not FDA-approved and has not been reviewed for safety, quality, or potency.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.